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Abstract
Monoclonal antibodies (mAbs) that bind and neutralize human pathogens have great therapeutic 
potential. Advances in automated screening and liquid handling have resulted in the ability to 
discover antigen-specific antibodies either directly from human blood or from various 
combinatorial libraries (phage, bacteria or yeast). There remain, however, bottlenecks in the 
cloning, expression and evaluation of such lead antibodies identified in primary screens that 
hinder high-throughput screening. As such, ‘hit-to-lead identification’ remains both expensive and 
time-consuming. By combining the advantages of overlap extension PCR (OE-PCR) and a 
genetically stable yet easily manipulatable microbial expression host Pichia pastoris, we have 
developed an automated pipeline for the rapid production and screening of full-length antigen-
specific mAbs. Here, we demonstrate the speed, feasibility and cost-effectiveness of our approach 
by generating several broadly neutralizing antibodies against human immunodeficiency virus 
(HIV).
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Monoclonal antibodies (mAbs) are high-value biologics, an important class of therapeutic 
agents used to treat a wide range of diseases, generating ~ $20 billion in revenue annually 
(Aggarwal, 2014). High-throughput tools now exist to identify antibodies against key human 
pathogens including HIV, influenza and dengue virus (Wilson and Andrews, 2012). The 
initial identification of antibody candidates can be carried out using binding kinetics of 
smaller fragments (including single-chain variable fragments (scFv) or antigen-binding 
fragments (Fab)), but complete functional characterization, including bioactivity, 
neutralization potential and antibody-dependent cell-mediated cytotoxicity (ADCC) etc., 
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requires moderate quantities (~ 0.1 – 1 mg) of the expressed full-length material 
(Hoogenboom, 2005).
Historically, the screening and production of antibodies has involved the creation of 
hybridomas or Epstein-Barr virus (EBV) transformed human B cells, followed by limiting 
serial dilution to recover antigen-specific clones (Wang, 2011). Generating full-length 
antibodies using these techniques is not only time-consuming, but often results in low 
material yields from the initial clonal stock (Frame and Hu, 1990). The ability to amplify the 
variable regions of an antibody (VH and VL) by PCR and clone them directly into 
expression plasmids has preempted the need for traditional hybridoma technology, allowing 
researchers to recombinantly produce mAbs from various host organisms, most commonly 
HEK 293T or CHO cell lines.
Recently, methods for the direct amplification of variable regions from single cells via 
reverse transcription-PCR (RT-PCR) have been developed (Tiller et al., 2008; Wang and 
Stollar, 2000). These advances have greatly expanded access to the human antibody 
repertoire, but bottlenecks in the expression of antibodies persist, hindering rapid ‘hit-to-
lead’ identification. In particular, cloning of antibody variable regions through bacterial 
propagation and transfection of two separate expression vectors (containing heavy and light 
chain genes respectively) are time-consuming steps that require separate aseptic workspaces, 
expensive reagents (such as lipofectamine) as well as skilled personnel. The use of linear 
expression vectors constructed through overlap-extension PCR (OE-PCR) (Liao et al., 2009) 
has precluded the need for bacterial propagation, but still requires transient co-transfection.
There has been a strong interest in developing microbial expression systems for the purposes 
of antibody production (Spadiut et al., 2014). The methyloptropic yeast Pichia pastoris has 
emerged as a promising eukaryotic host in this area, owing to its strong but tightly regulated 
alcohol oxidase I promoter (PAOX1), rapid growth on inexpensive media and limited risk for 
viral contamination. Additionally, GlycoFi and GlycoSwitch technologies have led to the 
humanization of Pichia’s glycosylation pathway, allowing for the production of mAbs with 
human-like glycoforms that are comparable in potency and efficacy CHO-derived products 
(Meehl and Stadheim, 2014; Spadiut et al., 2014). Transformation of Pichia results in stable 
chromosomal integration of the expression vector, further facilitating strain generation and 
screening in a high-throughput and/or automated fashion (Barnard et al., 2010; Jiang et al., 
2010).
Here, we have combined the advantages of overlap extension PCR (OE-PCR) and the Pichia 
pastoris expression system to develop an integrated and automated pipeline for the 
generation of full-length mAbs. We demonstrate our approach through the rapid generation 
of stable mAb-producing Pichia strains for the expression and screening of broadly 
neutralizing antibodies (bnAbs) against HIV. Overall, our strategy enables rapid and cost-
effective hit-to-lead identification for antibody development and could be adapted, in 
principle, to screen for specific mAbs against any infectious agent for which an antigen is 
available.
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Currently, mAb production in Pichia is carried out using expression plasmids containing 
two separate promoter elements for expression of heavy and light chain genes cloned 
through the conventional bacterial propagation process (Zha, 2013). We used the foot-and-
mouth disease virus (FMDV) 2A sequence to eliminate one promoter and enable bicistronic 
expression of heavy and light chains from a single open reading frame (ORF). Our strategy 
also minimizes the size of the expression construct (~ 6 Kb), thereby promoting PCR 
assembly as well as genetic stability at the integration loci (Zhu et al., 2009). The 2A 
sequence has been previously used for the production of full-length antibodies from 
mammalian cells (Fang et al., 2005) and has been effective in the coexpression of digestive 
enzymes in Pichia (Roongsawang et al., 2010). Figure 1 presents a schematic outlining the 
key features and steps for assembly of our expression construct. Heavy and light chains are 
expressed using the PAOX1 promoter and secreted using the α-factor secretion signal at their 
5′ ends (Fig. S1). The light chain is placed in front of the heavy chain; previous observations 
have shown that an excess of light chain can promote folding and increase antibody stability 
(Schlatter et al., 2008). We used the Kanamycin marker for G418-based selection of 
transformed strains (Scorer et al., 1994), as opposed to Zeocin-based selection, due to its 
relative cost-effectiveness, potential for automation and the sensitivity of Zeocin to light. 
Variable region fragments (VL and VH) originating either directly from RT-PCR of 
antibody-secreting cells or from synthesized genes are amplified using primers containing 
complimentary flanking sequences and incorporated into the light and heavy chain segments 
by OE-PCR. These two DNA segments, along with a segment that contains the selectable 
marker, are then assembled together to generate the full construct (Fig. 1A). Transformation 
of this vector into Pichia by electroporation (Fig. 1B) results in stable integration at the 
AOX1 locus with nearly 100% correct integration frequency (as verified by PCR).
We found two design features were essential to facilitate robust assembly of the expression 
construct: (1) large regions of overlap between parts and (2) carefully designed primers with 
high annealing temperatures (60°C – 65°C). By incorporating these considerations, we 
generated clean PCR products without non-specific amplification during each stage of 
assembly and proceed to subsequent steps without the need for any gel or column 
purification of assembled intermediates. As a representative example, Figure 2 shows PCR 
assembly of a construct for the expression of aglycosylated b12 (N297Q), a broadly 
neutralizing antibody against HIV. Our strategy allows such expression constructs to be 
generated routinely in less than 2 days without the need for any bacterial propagation. The 
modular nature of this assembly process also enables facile swapping of constituent parts 
(Fig. S1), including exchanging of the native Fc backbone for Fc domain variants in order to 
generate antibodies with diverse effector functions (Sazinsky et al., 2008). Finally, the entire 
process for assembling expression constructs has been designed in a manner amenable to 
high-throughput automation.
Next, we developed an automated pipeline (Fig. 3A) for expression and functional screening 
that includes (1) outgrowth and induction of mAb-producing Pichia strains in 24 or 96-well 
deep-well plates, (2) clarification of culture media through centrifugation, (3) purification of 
full-length antibodies from the culture supernatant using Protein A-resin tips and (4) binding 
assays to determine expression titer and binding affinities of purified full-length mAbs using 
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a liquid handling system. To test this platform, we used our OE-PCR assembly to generate 
constructs for the evaluation of three more aglycosylated mAbs against HIV: one described 
previously in the literature (479, (Scheid et al., 2009; Scheid et al., 2011)) and one 
discovered using a microengraving-based approach (MIT-41, (Ogunniyi et al., 2014)). 
Owing to the modular nature of our assembly process, we also simultaneously generated 
constructs for two additional variants of b12 and MIT-41 antibodies containing modified Fc 
regions – (1) G236A/S239D/A330L/I332E [GASDALIE], which enhances activating FcγR 
binding and (2) G236R/L328R [GRLR], which abolishes FcγR binding (Bournazos et al., 
2014). These expression constructs were electroporated into competent Pichia cells and 6 – 
8 transformants for each antibody construct were selected for our automated platform for 
mAb expression and evaluation. To test the fidelity of the OE-PCR assembly process, we 
also isolated genomic DNA from all 60 clones selected for mAb expression and verified the 
sequence of the integrated construct using Sanger sequencing. In all cases, we found a 100% 
homology between the designed and integrated construct, suggesting that the error rate of 
our OE-PCR assembly is likely determined by the fidelity of the DNA polymerase used.
Upon putting the transformants through our automated expression platform, we found that 
titers of full-length mAbs in deep-well plates ranged between 100 – 500 ng/mL and were 
sufficient to carry out assays to (1) confirm production of full-length antibody, (2) determine 
the best-producing isolate and (3) identify binders to a specific antigen (in this case HIV 
coat protein gp120). Purified antibodies were analyzed by SDS-PAGE (Fig. 3B, non-
reducing and Fig. 3C, reducing) and western blot analysis (Fig. S2A, non-reducing and Fig. 
S2B, reducing). Our results show the presence of fully assembled antibody (~ 150 kDa) 
along with several other fragments that are typically observed in unfractionated Protein A 
affinity-purified eluates. We also found the presence of fragmented heavy chain (Fig. S2), 
which is likely a result of residual proteolytic activity from host cell proteins (HCPs) - a well 
known issue and common occurrence in the production of therapeutic antibodies (Gao et al., 
2010). When subjected to gp120 binding assays (native Fc, Fig. 3D and Fc variants, Fig. 
3E), we found that the full-length Pichia-derived aglycosylated b12 mAb had a binding 
affinity for gp120 similar to standard CHO-derived glycosylated b12 mAb. Our results also 
showed that the MIT-41 mAb has a gp120 binding affinity similar to that of b12 mAb, 
suggesting it as a suitable candidate for further functional testing (virus neutralization, 
ADCC etc.).
In conclusion, our data show that we can produce full-length and functional antibodies using 
the OE-PCR strategy in a rapid and flexible manner. The use of the 2A peptide sequence 
simplifies vector design for production of mAbs in Pichia. Most importantly, the time 
required to translate a set of VL and VH from genes into antibody using our pipeline is ~ 12 
days, and can be carried out in an automated and high-throughput fashion. While we have 
demonstrated production of aglycosylated mAbs from a wild-type Pichia strain, this strategy 
can be readily adapted for the expression and evaluation of glycosylated mAbs from 
glycoengineered Pichia strains (Meehl and Stadheim, 2014; Spadiut et al., 2014). Overall, 
we believe that our approach provides advantages over current methodologies with respect 
to time and costs (Table I and Table S2). Combining it with a production-ready/optimized 
host (i.e. glycoengineered and/or super-secretor strain) will further accelerate lead 
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optimization, as scale up from plate-based testing to fermentation in bioreactors does not 
require changing the expression host or re-cloning the constructs. Our approach should 
facilitate the characterization of many new mAbs in a shorter amount of time and with fewer 
material and personnel resources.
Materials and Methods
OE-PCR assembly
KOD Hot Start Xtreme polymerase (EMD Millipore, Cat. No. 71975) was used for all PCR 
reactions. Sequences of primers and steps used for OE-PCR assembly are described in 
Supplementary Material. Initial DNA fragments were synthesized using Invitrogen’s gene 
synthesis service and amplified from their vectors using the following thermocycler 
conditions: 94°C for 2 min, followed by 30 – 35 cycles of 94°C for 20 s, 65°C for 15 s and 
72°C for 1 min/kb (25 μL reaction volume, ~ 1 ng template). The three segments – (1) light 
chain, (2) heavy chain and (3) selectable marker were then assembled from these amplified 
fragments. For each segment, an extension step without primers was first carried out using 
the following conditions: 94°C for 2 min, followed by 12 cycles of 94°C for 20 s, 45°C for 
15 s and 72°C for 1 min. Then, 2 μL of each piece was used as template to amplify the 
segments using the following conditions: 94°C for 2 min, followed by 32 cycles of 94°C for 
20 s, 65°C for 15 s and 72°C for 1 min/kb. Finally, 2 μL template from each amplified 
segment was pooled together and used for full construct assembly using two-step PCR 
conditions: 94°C for 2 min, followed by 35 cycles of 94°C for 20 s and 72°C for 6 min. 
Multiple reactions were carried out to generate 5 – 10 μg of DNA followed by isopropanol 
precipitation down to a volume of 10 μL for electroporation into Pichia.
Transformation and cultivation of Pichia strains
A wild-type Pichia pastoris strain (Komagataella phaffii, NRRL Y-11430, ATCC 76273) 
was used in this study. Competent cell preparation, electroporation and cultivation were 
carried out as described in the Invitrogen Pichia manual (Aitchison, 2009). Transformants 
were selected on YPD+Sorbitol media containing 500 ug/mL Geneticin (Invitrogen, Cat. 
No. 10131-035) and freezer stocks were made in YPD + 20% glycerol. Strains were 
outgrown and induced using standard BMGY and BMMY media (Teknova, Cat. No. B8000 
and B8100 repectively) containing 0.1% Sigma A204 antifoam and supplemented with 1% 
methanol every 24 hours in BMMY media. After ~ 72 hours of induction, cells were spun 
down at 3000 rpm for 5 min and clarified supernatant was transferred to fresh plates for 
purification of mAbs.
Protein A purification
mAb-containing supernatants were purified on a Tecan Freedom Evo 150 liquid handling 
system with an MCA96 head using tips containing 20 μL of Protein A resin and according to 
manufacturers instructions. (PhyNexus, Cat. No. PTM 92-20-01).
SDS-PAGE and Western blot
Purified mAb samples were denatured at 90°C for 30 minutes before running on 12% 
precast gels (Bio-Rad, Cat. No. 456-1044). 50mM Dithiothreitol (DTT) was used as 
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reducing agent. For western blot analysis, mouse anti-human Fc specific IgG (Millipore, 
Cat. No. MAB1302) was used at a 1:1000 dilution to detect heavy chain and mouse anti-
human kappa specific IgG (Abcam, Cat. No. ab1050) was used at a 1:1000 dilution to detect 
light chain. Goat anti-mouse IgG (Abcam, ab97040) was used as secondary antibody in both 
cases.
Immunoassays
Two sandwich ELISAs were validated for use on the Tecan liquid handling system. For the 
detection of full-length antibody and determination of mAb titers, goat anti-human Fc 
specific IgG (Jackson ImmuneR, Cat. No. 109-005-098) was used as capture antibody (5 
μg/mL) and HRP-conjugated goat anti-human kappa chain specific IgG (Invivogen, Cat. No. 
hrp-igak) as the detection antibody (500 ng/mL). For determination of binding affinity to 
gp120, the same goat anti-human Fc specific IgG capture antibody was used (5 μg/mL), 
followed by addition of sample, gp120 (1 ug/mL) and HRP-conjugated goat anti-gp120 
(Pierce, Cat. No. PA1-73097) as detection antibody (500 ng/mL). For both assays, signal 
was developed using the QuantaBlu Fluorogenic Peroxidase Substrate Kit (Thermo, Cat. No 
15169) and read with excitation and emission wavelengths set at 325 nm and 420 nm 
respectively. CHO-derived b12 (Cat. No 2640), used as a standard throughout this work, 
was obtained through the NIH AIDS Research and Reference Reagent program, Division of 
AIDS, NIAID, NIH.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Schematic of OE-PCR based construct and steps for expression of monoclonal antibodies 
using Pichia pastoris. A: Heavy and light chain variable regions (VH and VL) are 
incorporated into the assembly process using primers containing adapter sequences. CH and 
CL – constant region sequences for heavy and light chain, 2A – FMD virus ribosome skip 
sequence, PAOX – alcohol oxidase promoter, KanR – G418 resistance marker. The three 
segments (containing light chain, heavy chain and selectable marker) are assembled together 
to generate the full construct. B: The assembled full construct is electroporated into Pichia 
where it stably integrates into the genome. Upon methanol induction, antibodies are 
expressed and secreted by transformed cells into the culture media.
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Figure 2. 
Stepwise assembly of an expression construct. Heavy and light chain variable regions (VH 
and VL), originating either from RT-PCR of antigen-specific antibody-secreting cells or 
from synthesized genes, along with other pre-amplified pieces are incorporated into 
segments using OE-PCR. Each of the three amplified segments are then pooled and 
assembled together using the same method. 3′ PAOX and 5′ PAOX are the 3′ and 5′ portions 
of the whole promoter one would obtain when cleaving with the MssI restriction enzyme. 
This design facilitates integration into the AOX1 locus through a single crossover event.
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Figure 3. 
Automation of antibody production pipeline and confirmation of full-length and functional 
mAbs using the OE-PCR approach. A: (i) Transformed Pichia strains are outgrown and 
induced in 96 or 24-well deep-well plates. (ii) The plates are then spun down for 
clarification of culture media and (iii) mAbs are purified from the supernatant using Protein 
A resin-containing tips on a liquid handling system. (iv) Automated ELISAs confirm 
production of mAb, identifying best-producing isolate as well as determining antigen 
binding. B: and C: SDS-PAGE of Pichia-derived mAbs under non-reducing (B) and 
reducing conditions (C). Fc variants shown here are 1 - GASDALIE and 2 - GRLR. D: and 
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E: HIV-gp120 binding curves of Pichia-derived (Pp) mAbs generated using automated 
ELISA assays for antibodies with native Fc backbone (D) or Fc variant backbone (E). 
Figures plotted using mean fluorescence units (RFU) and error bars show standard deviation 
derived from triplicate measurements.
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Table I
Comparison between methods for cloning and expression of mAbs
Cloning-based mammalian cell derived 
mAbs OE-PCR-based Pichia derived mAbs
Steps during construction of expression vector PCR, gel/column purification, ligation, bacterial propagation PCR only
Host organisms required E. coli and HEK or CHO Pichia pastoris
Culture media Animal-derived Animal-free
Viral contamination risks High Low (no endogenous viruses)
Genetic stability of expression vector Transient transfection Stable chromosomal integration
Amenable to scale up No Yes
Automation-friendly No Yes
Time from VL & VH genes to antibody 30 – 60 days 12 – 14 days
Cost per 100 ug of 96 antibodies (raw materials only) > $ 3000 ~ $ 1500
FTE requirements Multiple Single
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